unknown
Stage
About
Velicept was developing solabegron, a selective beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). The company ceased operations in 2020.
Explore Velicept's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.